Study Reveals Ozempic’s Surprising Benefits and Risks

ST. LOUIS, Mo. — A groundbreaking study has uncovered both significant health benefits and potential risks associated with Ozempic and similar GLP-1 drugs, widely used for diabetes and obesity treatment. The research, conducted by Washington University School of Medicine and the Veterans Affairs St. Louis Health Care System, analyzed data from over two million veterans between 2017 and 2023.

The study, published in the journal Nature, found that GLP-1 drugs, including Ozempic, reduced risks of neurocognitive disorders, addiction, suicidal ideation, and psychotic disorders. “GLP-1s have many benefits for at least 42 conditions beyond weight loss,” said lead author Dr. Ziyad Al-Aly, a clinical epidemiologist at Washington University.

However, the research also highlighted serious side effects, including potential harm to the pancreas and kidneys, and an increased risk of arthritis. “While these adverse effects are uncommon, they can be very serious,” Al-Aly cautioned, emphasizing the need for vigilant monitoring by healthcare providers.

The study’s findings come as one in eight U.S. adults has reportedly used Ozempic or similar medications. Dr. Seth Kipnis, a bariatric surgery expert, noted that while weight loss can improve overall health, proper nutritional education is crucial to mitigate risks. “If you take these medications without nutritional education, they can be harmful,” he warned.

Novo Nordisk, the manufacturer of Ozempic, reiterated its commitment to patient safety, stating that the known risks and benefits are clearly outlined in FDA-approved labeling. The company continues to explore the potential of semaglutide, the active ingredient in Ozempic, for treating other chronic diseases.

As GLP-1 drugs gain popularity, experts urge patients to weigh the benefits and risks with their healthcare providers. “Each person’s health profile is different. Pros and cons should be discussed with the provider,” Al-Aly advised.